Literature DB >> 12174096

Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3.

S W Cheng1, M Kobayashi, K Kinoshita-Kuroda, A Tanikawa, M Amagai, T Nishikawa.   

Abstract

BACKGROUND: Pemphigus is an antidesmoglein (Dsg) autoimmune disease that is divided into two major subtypes: pemphigus foliaceus (PF) and pemphigus vulgaris (PV). We previously developed enzyme-linked immunosorbent assays (ELISAs) using recombinant Dsg1 and Dsg3 to detect IgG autoantibodies in patients with pemphigus. The protocol for the ELISAs was optimized for serological diagnosis, but under the conditions used, these assays were not particularly useful for monitoring disease activity in certain patients. That is, the sera from some patients with high-titre antibodies continued to show high index values in the ELISA after clinical improvement.
OBJECTIVES: In the study reported here, we modified the ELISA protocol to obtain 'true' index values that exhibit a better correlation with disease activity.
METHODS: We tested two cases of pemphigus foliaceus (PF) and four cases of pemphigus vulgaris (PV), each with ELISA index values greater than 150 for Dsg1 or Dsg3. We ran an ELISA with sera from these patients serially diluted from 1 : 100 to 1 : 12,800. We then performed ELISA with a series of PV No. 1 sera diluted to 1 : 800 and PV No. 2-4 and PF No. 1-2 sera diluted to 1 : 1600, after which we plotted the ELISA index values against the time course of disease activity.
RESULTS: In each of these cases, there was no apparent decline, over the course of the disease activity, in the ELISA index values at a serum dilution of 1 : 100, probably because the antigen-antibody reaction was saturated at that dilution. After running an ELISA with sera serially diluted from 1 : 100 to 1 : 12,800 we found that a linear dose-dependency between the dilution value and the index value was only observed when sera were diluted to 1 : 800 or more in one case (PV No.1) and to 1 : 1600 or more in the other five cases (PV No. 2-4, PF No. 1-2). After performing ELISA with these series as outlined above we plotted the ELISA index values against the time course of disease activity and found that the index values obtained from these appropriately diluted sera fluctuated in parallel with disease activity, and declined with clinical improvement.
CONCLUSIONS: These findings indicate that when appropriate dilutions are used in Dsg1 and Dsg3 ELISA, these assays can provide useful serological information for assessing disease activity in PF and PV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174096     DOI: 10.1046/j.1365-2133.2002.04838.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  24 in total

Review 1.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 2.  Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.

Authors:  Christoph M Hammers; John R Stanley
Journal:  Annu Rev Pathol       Date:  2016-02-22       Impact factor: 23.472

3.  Pemphigus vulgaris localized to the tongue.

Authors:  Tegan Nguyen; Abdul Razzaque Ahmed
Journal:  J Dermatol Case Rep       Date:  2014-06-30

4.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; L Ashkenazi; Y Milner; M Frusic-Zlotkin; G J Anhalt; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 5.  Diagnosis and clinical features of pemphigus foliaceus.

Authors:  Kirk A James; Donna A Culton; Luis A Diaz
Journal:  Dermatol Clin       Date:  2011-07       Impact factor: 3.478

6.  Enrichment of total serum IgG4 in patients with pemphigus.

Authors:  T Funakoshi; L Lunardon; C T Ellebrecht; A R Nagler; C E O'Leary; A S Payne
Journal:  Br J Dermatol       Date:  2012-09-27       Impact factor: 9.302

Review 7.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

8.  Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.

Authors:  Christoph T Ellebrecht; Eun J Choi; David M Allman; Donald E Tsai; William A Wegener; David M Goldenberg; Aimee S Payne
Journal:  JAMA Dermatol       Date:  2014-12       Impact factor: 10.282

9.  Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

Authors:  Luisa Lunardon; Kathleen J Tsai; Kathleen J Propert; Nicole Fett; John R Stanley; Victoria P Werth; Donald E Tsai; Aimee S Payne
Journal:  Arch Dermatol       Date:  2012-09

10.  Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up.

Authors:  Anna Belloni-Fortina; Diana Faggion; Barbara Pigozzi; Andrea Peserico; Matteo Bordignon; Vincenzo Baldo; Mauro Alaibac
Journal:  Clin Dev Immunol       Date:  2009-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.